Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 1.00 |
| ▸ | CA2 | P00918 | 6/20 | 1.00 |
| ▸ | CA9 | Q16790 | 4/20 | 1.00 |
| ▸ | CA12 | O43570 | 3/20 | 1.00 |
| ▸ | CA3 | P07451 | 1/20 | 1.00 |
| ▸ | CA6 | P23280 | 1/20 | 1.00 |
| ▸ | CA5A | P35218 | 1/20 | 1.00 |
| ▸ | CA7 | P43166 | 1/20 | 1.00 |
| ▸ | CRBN | Q96SW2 | 1/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 1.00 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.50 |
| ▸ | PTGES2 | Q9H7Z7 | 5/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indisulam SCHEMBL29799438 | 1.00 | CA1 (1.00) | CA1CA2CA9CA12CA3 | |
| SCHEMBL3062409 | 0.91 | CA1 (0.83) | CA1CA2CA9CA12CA3 | |
| SCHEMBL14536224 | 0.89 | CA1 (0.80) | CA1CA2CA9CA12CA3 | |
| SCHEMBL12190471 | 0.88 | CA1 (0.79) | CA1CA2CA9CA12CA3 | |
| SCHEMBL7006391 | 0.88 | CA1 (0.79) | CA1CA2CA9CA12CA3 | |
| SCHEMBL3073932 | 0.88 | CA1 (0.79) | CA1CA2CA9CA12CA3 | |
| SCHEMBL27634530 | 0.88 | CA1 (0.79) | CA1CA2CA9CA12CA3 | |
| SCHEMBL3068188 | 0.88 | CA1 (0.79) | CA1CA2CA9CA12CA3 | |
| SCHEMBL3071891 | 0.88 | CA1 (0.78) | CA1CA2CA9CA12CA3 | |
| SCHEMBL26265974 | 0.87 | CA1 (0.77) | CA1CA2CA9CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 886 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720329-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS HAVING A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSTIC METHOD | SensID GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| EP-4694892-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TOPOISOMERASE INHIBITOR, A SPLICING INHIBITOR SULFONAMIDE, OR A KIF18 INHIBITOR | Ideaya Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| US-12551527-B2 | Drug delivery systems for treatment of infections | WAYNE STATE UNIVERSITY (US) | 2026-02-17 | — | — | US | claimed |
| US-12428459-B2 | Protein tag to induce ligand dependent degradation of protein/protein-fusions | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-09-30 | — | — | US | claimed |
| US-20250295693-A1 | HYBRID TUMOR/CANCER THERAPY BASED ON TARGETING THE RESOLUTION OF OR INDUCING TRANSCRIPTION-REPLICATION CONFLICTS (TRCS) | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2025-09-25 | — | — | US | claimed |
| WO-2025063888-A1 | SURVIVIN-TARGETED COMPOUNDS | KANCURE PTE. LTD. (SG) | 2025-03-27 | — | — | WO | claimed |
| WO-2025051337-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING ORAL CANCER | Afyx Development A/S (DK) | 2025-03-13 | — | — | WO | claimed |
| WO-2024246014-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS HAVING A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSTIC METHOD | SENSID GMBH (DE) | 2024-12-05 | — | — | WO | claimed |
| EP-4467659-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS WITH A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSIS | SensID GmbH (DE) | 2024-11-27 | — | — | EP | claimed |
| WO-2024216145-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TOPOISOMERASE INHIBITOR, A SPLICING INHIBITOR SULFONAMIDE, OR A KIF18 INHIBITOR | IDEAYA BIOSCIENCES, INC. (US) | 2024-10-17 | — | — | WO | claimed |
| EP-1622624-A1 | MEDICINAL COMPOSITIONS COMPRISING N-(3-CHLORO-1H-INDOL-7-YL)-4-SULFAMOYLBENZENESULFONAMIDE AND FURTHER CYTOSTATICS | Eisai Co., Ltd. (JP) | 2006-02-08 | — | — | EP | claimed |
| WO-2004098613-A1 | MEDICINAL COMPOSITIONS COMPRISING N-(3-CHLORO-1H-INDOL-7-YL)-4-SULFAMOYLBENZENESULFONAMIDE AND FURTHER CYTOSTATICS | EISAI CO., LTD. (JP) | 2004-11-18 | — | — | WO | claimed |
| US-20040224972-A1 | Medicinal compositions for concomitant use as anticancer agent | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-11-11 | — | — | US | claimed |
| US-20040002505-A1 | Medicinal compositions for cocominant use as anticancer agent | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-01-01 | — | — | US | claimed |
| EP-0673937-B1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | EISAI CO LTD (JP) | 2003-11-26 | — | — | EP | claimed |
| US-20030215523-A1 | Medicinal compositions for concomitant use as anticancer agent | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| EP-1331005-A1 | MEDICINAL COMPOSITIONS FOR CONCOMINANT USE AS ANTICANCER ATENT | Eisai Co., Ltd. (JP) | 2003-07-30 | — | — | EP | claimed |
| US-6060498-A | Composition containing antitumor agent | EISAI CO., LTD. (JP) | 2000-05-09 | — | — | US | claimed |
| EP-0923932-A1 | COMPOSITION CONTAINING ANTITUMOR AGENT | Eisai Co., Ltd. (JP) | 1999-06-23 | — | — | EP | claimed |
| EP-0673937-A1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224972-A1 | Medicinal compositions for concomitant use as anticancer agent | MTDH, TOP2B, TOP1 | CA1 490/4885CA2 834/4885CA9 432/4885 |
| US-12551527-B2 | Drug delivery systems for treatment of infections | PHOSPHO1, PCTP, SGMS1 | CA1 3994/4885CA2 4705/4885CA9 4426/4885 |
| US-20030215523-A1 | Medicinal compositions for concomitant use as anticancer agent | MTDH, TOP2B, TOP1 | CA1 490/4885CA2 834/4885CA9 432/4885 |
| US-20040002505-A1 | Medicinal compositions for cocominant use as anticancer agent | MTDH, TOP2B, CCNH | CA1 1895/4885CA2 1930/4885CA9 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.